deltatrials
Completed PHASE2 NCT00659360

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma

Sponsor: National Cancer Institute (NCI)

Conditions Adult Fibrosarcoma Adult Leiomyosarcoma Adult Liposarcoma Adult Malignant Fibrous Histiocytoma Adult Rhabdomyosarcoma Dermatofibrosarcoma Protuberans Endometrial Stromal Sarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Uterine Sarcoma Stage III Adult Soft Tissue Sarcoma Stage III Uterine Sarcoma Stage IV Adult Soft Tissue Sarcoma Stage IV Uterine Sarcoma Uterine Carcinosarcoma Uterine Leiomyosarcoma
Interventions saracatinib
Updated 9 times since 2017 Last updated: May 29, 2018 Started: Feb 29, 2008 Primary completion: Jan 31, 2009 Completion: Nov 30, 2012

Listed as NCT00659360, this PHASE2 trial focuses on Adult Fibrosarcoma and Adult Leiomyosarcoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jul 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Edmonton, Canada
  • • Montreal, Canada
  • • Rockledge, United States
  • • Toronto, Canada